louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT03913520: Outcome of Patients With Congenital Heart Disease
Official title: Postoperative Outcome of Patients With Congenital Heart Disease Presenting for Non-cardiac Interventions
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Congenital Heart Disease
Lead sponsor: Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Sponsor class: OTHER
First posted: 2019-04-12
Enrollment: 150
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: OTHER

Brief summary: Advanced surgical and medical healthcare systems have resulted in an increased prevalence of children and adults with congenital heart disease in Western countries. These patients often necessitate non-cardiac interventions. Previous studies have demonstrated that these patients are at increased risk of morbidity and mortality when presenting for non-cardiac interventions. The aim of this study is to know the prevalence of patients with congenital heart disease presenting for non-cardiac interventions in a tertiary hospital and to determine their outcome.

Detailed description: Previous studies have shown that children and adults presenting with congenital heart disease are at increased risk of morbidity and mortality after non-cardiac interventions. This risk depends on the type of pathology, the age of the patient and the experience of the physicians in charge of these patients.

We sought to determine the prevalence of children and adults with congenital heart disease presenting for non-cardiac interventions and to investigate their outcome.

Eligibility criteria: Inclusion Criteria:

* All children and adults with congenital heart disease

Exclusion Criteria:

* Parental or patient refusal
* Patients presenting for cardiac interventions

Primary outcomes:
measure: The prevalence of patients with congenital heart disease presenting for non-cardiac interventions in a single-centre tertiary hospital
timeFrame: Intraoperative
Secondary outcomes:
measure: To analyze morbidity after non-cardiac interventions in patients with congenital heart disease
timeFrame: 30 days
measure: To analyze mortality after non-cardiac interventions in patients with congenital heart disease
timeFrame: 30 days
Other outcomes:
Locations:
city: Brussels
country: Belgium
facility: Cliniques Universitaires Saint Luc
Study officials:
affiliation: Cliniques universitaires Saint-Luc- Université Catholique de Louvain
name: Mona MOMENI, MD,PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00729820: The Influence of Personality on Two Aspects of Cognitive Performance: Processing Speed, and Accuracy.
Official title: The Influence of Personality on Two Aspects of Cognitive Performance: Processing Speed, and Accuracy.
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Healthy
Keywords: PERSONALITY
COGNITIVE PERFORMANCE
the practical usefulness (validity) of processing speed, accuracy of performance and personality measures in predicting impulsive behavior
Lead sponsor: BeerYaakov Mental Health Center
Sponsor class: OTHER_GOV
First posted: 2008-08-08
Enrollment: 30
Sex: ALL
Minimum age (years): 20
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: no
Sampling method: NON_PROBABILITY_SAMPLE
Study population: 1. Men and women at age - 20-50 years
2. The following demographic and anamnesis' data should be readily available:

Age, ethnicity, marital and educational status. History of physical disorders and pharmacological treatments.

Brief summary: Recently, a lot of evidence for a relation between measures of cognitive performance and personality characteristics has been collected. The use of computer based latency measures is often used to study mental processes in cognitive, as well as, in personality research On the basis of these relationships we can ask a question that relates to the practical usefulness (validity) of processing speed, accuracy of performance and personality measures in predicting impulsive behavior.


Eligibility criteria: Inclusion Criteria:

* Men and women at age - 20-50 years

Exclusion Criteria:

* History of psychiatric disorders, previous hospitalizations and psychopharmacological treatments
* History of alcohol and substance abuse

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT05667220: Sitagliptin in Combination With Beidougen Capsule for Type 2 Diabetes
Official title: Efficacy of Combination Therapy With Sitagliptin and Beidougen Capsule in Chinese Patients With Type 2 Diabetes
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: Type 2 Diabetes
Lead sponsor: Beijing Chao Yang Hospital
Sponsor class: OTHER
First posted: 2022-12-28
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: BASIC_SCIENCE

Brief summary: The study was an interventional non-randomized controlled study and was divided into a Sitagliptin monotherapy (100 mg Qd) group and a Sitagliptin (100mg Qd)+Beidougen capsule (60mg Tid) combination treatment group for one week.


Eligibility criteria: Inclusion Criteria:

* Patients aged 18-65 years with a first diagnosis of type 2 diabetes
* Diagnostic criteria HbA1c ≥ 7%

Exclusion Criteria:

* The positive of diabetes antibodies
* Anti-diabetic drugs therapy before participation
* Pancreatitis
* Coronary artery disease
* Liver function impairment
* Renal function impairment
* History of intestinal surgery
* Chronic hypoxic diseases (emphysema and cor pulmonale)
* Infectious disease
* Hematological disease
* Systemic inflammatory disease
* Cancer
* Pregnant
* Ingesting agents known to influence glucose or lipid metabolism
* Any antibiotics or probiotics in the past three months prior to the study

Primary outcomes:
measure: Fasting blood glucose change
timeFrame: Changes in fasting blood glucose from baseline to 1 week treatment
Secondary outcomes:
measure: Serum GLP-1 change
timeFrame: Changes in serum GLP-1 from baseline to 1 week treatment
measure: Fecal DPP4 activity change
timeFrame: Changes in fecal DPP4 activity from baseline to 1 week treatment
Other outcomes:
Locations:
city: Beijing
country: China
facility: Beijing Chao-yang Hospital, Capital Medical University
state: Beijing
Study officials:
affiliation: Beijing Chao Yang Hospital
name: Guang Wang, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02847520: Validation of a Tool for Assessing Gambling Problems Related to the Practice of Poker: the Copenhagen Poker Screen (CHAPS)
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Addiction
Keywords: Disorders related to gaming and gambling; poker
Lead sponsor: Nantes University Hospital
Sponsor class: OTHER
First posted: 2016-07-28
Enrollment: 729
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Poker players

Brief summary: If the addiction to games of chance and gambling is a disease of increasing knowledge, the emergence of poker rout evaluation procedures, prevention and treatment usually offered to players in need. In the case of poker, which unlike other games has a real part to address and which damages are expressed differently, the evaluation can not be done identically to other games. This problem has often been emphasized in the literature, in particular the lack of specific tools for the identification of poker gambling problems. Thus, the fact of developing a specific evaluation tool could allow poker to take into account the specificity of poker among other games. This would be part of the evaluation complement batteries currently available to players in general by offering a specific tool, and secondly to allow the assessment of the aspects of the problems often absent for other games . The goal here is to develop and validate a specific tool detection of problem gambling in the particular context of poker.


Eligibility criteria: Inclusion Criteria:

* All subjects who had a practice of poker over the past 12 months

Exclusion Criteria:

* Participants who have already completed the survey (on the basis of their declaration)

Primary outcomes:
measure: validate an evaluation tool of problem gambling within the specific framework of poker
timeFrame: 10 min
Secondary outcomes:
Other outcomes:
Locations:
city: Nantes
country: France
facility: CHU de Nantes
Study officials:
References:
Clinical trial NCT02873520: Precision Cell Immunotherapy Combined With Chemotherapy in Advanced Gastric Cancer
Official title: Clinical Study Using Precision Cell Immunotherapy Combined With Chemotherapy in Advanced Gastric Cancer
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE1
PHASE2
Conditions: Precision Cell Immunotherapy
Chemotherapy
Advanced Gastric Cancer
Keywords: Precision Cell Immunotherapy
Chemotherapy
Advanced Gastric Cancer
Lead sponsor: Ningbo Cancer Hospital
Sponsor class: INDUSTRY
First posted: 2016-08-19
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To evaluate the safety and effectiveness of cell therapy using Precision Cells to treat Advanced Gastric Cancer.

Eligibility:

Individuals greater than or equal to 18 years of age and less than or equal to 65 years of age who have been diagnosed with Advanced Gastric Cancer.

Detailed description: A total of 40 patients may be enrolled over a period of 1-2 years.

Eligibility criteria: Inclusion Criteria:

1. Age 18\~65 years old, male or female;
2. Life expectancy≥6 months;
3. ECOG score: 0-3;
4. Advanced Malignancies (gastric cancer) were diagnosed by pathological or clinical physicians;
5. Enough venous channel, no other contraindications to the separation and collection of white blood cells;
6. Laboratory examination: white blood cell≥3 x 10\*9/L, blood platelet count≥60 x 10\*/L,hemoglobin≥85g/L; lymphocyte count≥15%, total bilirubin≤100 mol/L; ALT and AST less than five times of the normal level; serum creatinine less than 1.5 times of the normal level；
7. Signed informed consent；8. Women of child-bearing age must have evidence of negative pregnancy test and be willing to practice birth control after 2 weeks following the cells transfusion.

Exclusion Criteria:

1. Expected Overall survival \< 6 months;
2. Patients with uncontrolled hypertension (\>160/95mmHg), unstable coronary disease (uncontrolled arrhythmias, unstable angina, decompensated congestive heart failure (\> Class II, NYHA), or myocardial infarction within 6 months.
3. Other serious diseases: nervous, mental disorders, immune regulatory diseases, metabolic diseases, infectious diseases, etc;
4. Other drugs, or other biological treatment,chemotherapy or radiotherapy are performed within a month.
5. Unable or unwilling to provide informed consent, or fail to comply with the test requirements.

Primary outcomes:
measure: Overall survival
timeFrame: 2 years
measure: Progress-free survival
timeFrame: 2 years
measure: Quality of life
timeFrame: 2 years
Secondary outcomes:
Other outcomes:
Locations:
city: Ningbo
country: China
facility: Ningbo No.5 Hospital (Ningbo Cancer Hospital)
state: Zhejiang
Study officials:
affiliation: Ningbo No.5 Hospital (Ningbo Cancer Hospital)
name: Jiangtao Wang
role: STUDY_DIRECTOR
affiliation: Shanghai Cell Therapy Research Institute
name: Huajun Jin
role: STUDY_CHAIR
affiliation: Shanghai Cell Therapy Research Institute
name: Qijun Qian
role: STUDY_CHAIR
References:
Clinical trial NCT04874220: Neural Correlates of Real World Spatial Navigation in Humans
Official title: Neural Correlates of Real World Spatial Navigation in Humans
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Memory, Delayed
Lead sponsor: University of California, Los Angeles
Sponsor class: OTHER
Collaborators: name: National Institute of Neurological Disorders and Stroke (NINDS)
First posted: 2021-05-05
Enrollment: 70
Sex: ALL
Minimum age (years): 12
Maximum age (years): 70
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: BASIC_SCIENCE

Brief summary: The purpose of this study is to understand the neural mechanisms that support real world spatial navigation in humans using deep brain recordings and stimulation during virtual reality (VR), augmented reality, and real world memory tasks. We will determine the cognitive (i.e., memory) and behavioral (i.e., body, head, eye position and movement) factors that modulate deep brain activity and the consequent effects of memory-enhancing deep brain stimulation.


Eligibility criteria: Inclusion Criteria:

* 12 years of age or older and has undergone RNS system placement
* Willing to provide informed consent and participate the study
* Ability to read and write English fluently

Exclusion Criteria:

* Unwilling to provide informed consent

Primary outcomes:
measure: Spatial memory
timeFrame: Throughout study completion, an average of 2-4 days per year
measure: Memory performance change
timeFrame: Throughout study completion, an average of 2-4 days per year
measure: Oscillatory activity change
timeFrame: Throughout study completion, an average of 2-4 days per year
Secondary outcomes:
Other outcomes:
Locations:
city: Los Angeles
country: United States
facility: University of California Los Angeles
state: California
Study officials:
affiliation: University of California, Los Angeles
name: Nanthia Suthana, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02025920: Project Healthy Eating in Adults. A Study on the Health Effects of Fish Intake in Overweight Adults (FINS)
Official title: Title in Norwegian: Sunn og Frisk. En Studie av Helseeffekter av Fiskeinntak i Overvektige Voksne (FINS)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Overweight or Obese Adults
Healthy
Lead sponsor: University of Bergen
Sponsor class: OTHER
Collaborators: name: The Fisheries and Aquaculture Industry Research Fund
First posted: 2014-01-01
Enrollment: 183
Sex: ALL
Minimum age (years): 20
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: It has previously been observed that increased fish intake improves the metabolic health of overweight and obese adults, and animal protein improved metabolic health of obese rats. In this project the investigators will investigate whether increased intake of fish or meat improves metabolic health in overweight/obese adults aged 20-55 years when replacing processed food. The hypothesis is that increased intake of unprocessed fish or meat will improve metabolic health in adults as measured by glucose tolerance, lipid metabolism and inflammatory markers.


Eligibility criteria: Inclusion Criteria:

* BMI \> 27
* 20-55 years
* healthy

Exclusion Criteria:

* diagnosed diseases such as diabetes, CVD, intestinal diseases, arthritis
* prescription medications affecting the metabolism of glucose, lipids or the immune system
* use of supplements containing long chain n-3 fatty acids
* high intake of fish
* food allergy

Primary outcomes:
measure: Changes in metabolic status (glucose, lipids, inflammation)
timeFrame: Baseline and end of intervention (12 weeks)
Secondary outcomes:
measure: Changes in plasma concentrations of amino acids and their metabolites
timeFrame: Baseline and end of intervention (12 weeks)
measure: Changes in plasma concentrations of vitamins
timeFrame: Baseline and end of intervention (12 weeks)
Other outcomes:
Locations:
city: Bergen
country: Norway
facility: University of Bergen
Study officials:
affiliation: University of Bergen
name: Oddrun A Gudbrandsen, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02995720: A Study to Compare the Pharmacokinetics and Safety of a Fixed Dose Combination of Fimasartan/Amlodipine/Rosuvastatin
Official title: An Open-label, Randomized, Single-dose, 2X3X3 Partial Replicate, Crossover Study to Compare the Pharmacokinetics and Safety Between a Fixed Dose Combination of Fimasartan/Amlodipine/Rosuvastatin and Co-administration of a Fixed Dose Combination of Fimasartan/Amlodipine and Rosuvastatin in Healthy Male Subjects
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Hypertension, Hyperlipidemia
Lead sponsor: Boryung Pharmaceutical Co., Ltd
Sponsor class: INDUSTRY
First posted: 2016-12-16
Enrollment: 60
Sex: MALE
Minimum age (years): 19
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: An open-label, randomized, single-dose, 2X3X3 partial replicate, crossover study to compare the pharmacokinetics and safety between a fixed dose combination of Fimasartan/Amlodipine/Rosuvastatin and Co-administration of a fixed dose combination of Fimasartan/Amlodipine and Rosuvastatin in healthy male subjects.


Eligibility criteria: Inclusion Criteria:

* Healthy male subject, aged 19- 50 years

Exclusion Criteria:

* History of clinically significant hypersensitivity to study drug, any other drug
* Hypotension or hypertension
* Active liver disease
* History of gastrointestinal disease
* History of excessive alcohol abuse
* Participation in any other study within 3 months

Primary outcomes:
measure: Cmax (Maximum concentration of drug in plasma) of Fimasartan, Amlodipine and Rosuvastatin
timeFrame: 0~72 hour after medication
measure: AUCt (Area Under the Curve from the dosing time to the last measurable concentration) of Fimasartan, Amlodipine and Rosuvastatin
timeFrame: 0~72 hour after medication
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT00250120: Pharmacology Study of Aerosolized Liposomal
Official title: Pharmacology Study of Aerosolized Liposomal 9-Nitro-20 (S) - Camptothecin (L9NC)
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE2
Conditions: Lung Diseases
Cancer
Keywords: NSCLC
L9NC
Aerosolized Liposomal 9-Nitro-20 (S)-Camptothecin
Lead sponsor: University of New Mexico
Sponsor class: OTHER
First posted: 2005-11-07
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: To determine the overall response rate to liposomal 9-Nitro-20 (S)-Camptothecin (L9NC) administered by aerosolization in patients with non-small-cell lung cancer (any stage).

To determine toxicity profile of L9NC administered by aerosolization for 5 consecutive days per week X 8 weeks, every 10 weeks.

To perform a pharmacology study of L9NC in the plasma, and the lungs after aerosolization. A specific protocol will be written for this part.

Detailed description: This is a single-arm, non-randomized Phase II trial of DLPC-9NC administered by aerosol 5 consecutive days per week for 8 weeks every 10 weeks.

Dose: 0.4 mg/ml of 9-NC in aerosol reservoir for 60 minutes (= daily dose of 0.52 mg/m2/day) per day X5 every week, X8 weeks, then observe for 2 weeks. One course = 10 weeks.

Patients that have a resectable lung cancer will only receive one course of treatment and will be operated on about two weeks after completing the 8-week course.

Eligibility criteria: Inclusion Criteria:

* Patients participating in INST 1402C protocol
* Phase II Study of Aerosolized Liposomal-Nitro-20 (S)-Camptothecin (L9NC) in Patients with Advanced (NSCLC) Lung Cancer are eligible if their tumor is resectable with curative intent as determined by Dr. Reza Mehran.

Primary outcomes:
measure: Pathological examination of lung tissure
timeFrame: at surgery
Secondary outcomes:
Other outcomes:
Locations:
city: Albuquerque
country: United States
facility: University of New Mexico
state: New Mexico
Study officials:
affiliation: University of New Mexico
name: Claire F Verschraegen, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06829420: Mirror Speech Entrainment: A Novel Technique for Voice Personalized Speech Entrainment for Nonfluent Aphasia
Official title: Mirror Speech Entrainment: A Novel Technique for Voice Personalized Speech Entrainment for Nonfluent Aphasia
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Aphasia Non Fluent
Stroke
Aphasia
Keywords: Aphasia
Nonfluent aphasia
Speech entrainment
Speech synchronization
Lead sponsor: University of South Florida
Sponsor class: OTHER
First posted: 2025-02-17
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The goal of this clinical trial is to test the use of voice personalization through artificial intelligence (AI) voice cloning on speech entrainment tasks to improve language production of persons with aphasia (PWA). The main question the study aims to answer is:

- What is the impact of personalized voice on speech entrainment in PWA compared to traditional speech entrainment?

Speech entrainment is a technique used by speech-language pathologists to improve the speech production of PWA. Traditionally, speech therapists act as the model for participants to speak along with to improve their speech production. This study proposes the use of one's own voice (digitally altered) to improve speech production.

The study uses a mobile health approach to administer speech entrainment treatment through a mobile app.

* Smartphones with the mobile app pre-installed will be mailed to participants at no cost.
* Participants will complete treatment in the comfort of their homes.
* The experimental treatments involve: mirror speech entrainment (speaking along to one's own voice) and traditional speech entrainment (speaking along to someone else's voice).


Eligibility criteria: Inclusion Criteria:

* Adults between the ages of 18-70 years old
* Dominant English-speaking
* Aphasia due to left hemisphere stroke

Exclusion Criteria:

* Individuals with aphasia due to other causes such as dementia, Alzheimer's disease and Parkinsonism
* Non-dominant English adult speakers
* Persons with significant difficulties with language comprehension
* Persons with concomitant cognitive disability
* Persons with uncorrected sensory deficits.

Primary outcomes:
measure: Speaking rate
timeFrame: From enrollment to the end of treatment at 6 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Tampa
country: United States
facility: University of South Florida
state: Florida
Study officials:
References: